Go to content
UR Home

A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14

Rentsch, Cyrill A. ; Thalmann, George N. ; Lucca, Ilaria ; Kwiatkowski, Maciej ; Wirth, Grégory J. ; Strebel, Räto T. ; Engeler, Daniel ; Pedrazzini, Augusto ; Hüttenbrink, Clemens ; Schultze-Seemann, Wolfgang ; Torpai, Raimund ; Bubendorf, Lukas ; Wicki, Andreas ; Roth, Beat ; Bosshard, Piet ; Püschel, Heike ; Boll, Daniel T. ; Hefermehl, Lukas ; Roghmann, Florian ; Gierth, Michael ; Ribi, Karin ; Schäfer, Simon ; Hayoz, Stefanie


Background: VPM1002BC is a geneticallymodifiedMycobacteriumbovis bacillus CalmetteGuerin (BCG) strain with potentially improved immunogenicity and attenuation. Objective: To report on the efficacy, safety, tolerability and quality of life of intravesical VPM1002BC for the treatment of non-muscle-invasive bladder cancer (NMIBC) recurrence after conventional BCG therapy. Design, setting, and ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons